
Keywords: Schilder's disease; Tumefactive multiple sclerosis; Myelinoclastic diffuse sclerosis; Rituxumab; MRI; Magnetic resonance image; CSF; Cerebral spinal fluid; VLCFA; Very long chain fatty acid; CNS; Central nervous system demyelinating disorder; IV; Intraven